{"Symbol": "APLM", "AssetType": "Common Stock", "Name": "Apollomics Inc. Class A Ordinary Shares", "Description": "Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company is headquartered in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.", "CIK": "1944885", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "989 EAST HILLSDALE BLVD., FOSTER CITY, CA, UNITED STATES, 94404", "OfficialSite": "https://www.apollomicsinc.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-03-31", "MarketCapitalization": "44924600", "EBITDA": "-41055000", "PERatio": "None", "PEGRatio": "None", "BookValue": "4.411", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-52.8", "RevenuePerShareTTM": "0.194", "ProfitMargin": "0", "OperatingMarginTTM": "10.07", "ReturnOnAssetsTTM": "-0.751", "ReturnOnEquityTTM": "-2.337", "RevenueTTM": "198000", "GrossProfitTTM": "198000", "DilutedEPSTTM": "-52.8", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "2.623", "AnalystTargetPrice": "2", "AnalystRatingStrongBuy": "-", "AnalystRatingBuy": "-", "AnalystRatingHold": "-", "AnalystRatingSell": "-", "AnalystRatingStrongSell": "-", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "6.12", "PriceToBookRatio": "8.12", "EVToRevenue": "5.08", "EVToEBITDA": "-0.0984", "Beta": "1.811", "52WeekHigh": "40.02", "52WeekLow": "3.659", "50DayMovingAverage": "17.09", "200DayMovingAverage": "9.14", "SharesOutstanding": "2143300", "SharesFloat": "542080", "PercentInsiders": "0.000", "PercentInstitutions": "0.669", "DividendDate": "None", "ExDividendDate": "None"}